Article
Oncology
Willard Wong, Edi Brogi, Jorge S. Reis-Filho, George Plitas, Mark Robson, Larry Norton, Monica Morrow, Hannah Y. Wen
Summary: The study evaluated the response to neoadjuvant chemotherapy in 44 patients with metaplastic breast carcinoma, finding that only 2% achieved a pathologic complete response, indicating poor response to NAC in most MpBC patients.
Article
Oncology
Tian Lan, Yunyan Lu, Ruzhen Zheng, Xiying Shao, Hua Luo, Junling He, Huifen Yang, Haibin Xu, Xiaojia Wang, Zujian Hu
Summary: This study found that chemotherapy did not improve breast cancer-specific death for operable metaplastic breast carcinoma patients, suggesting the need to reduce or reconsider current chemotherapy strategies. The results also identified race, tumor size, lymph node status, and radiation as significant factors affecting the prognosis of MBC patients.
FRONTIERS IN ONCOLOGY
(2021)
Article
Oncology
Asad Ullah, Jaffar Khan, Abdul Qahar Khan Yasinzai, Katharine Tracy, Tena Nguyen, Bisma Tareen, Andrea Agualimpia Garcia, Saleh Heneidi, Sheila E. Segura
Summary: Metaplastic breast carcinoma (MBC) is a rare and aggressive type of triple-negative breast cancer with poor prognosis. This study aimed to evaluate the demographics and characteristics of MBC, as well as survival outcomes based on presentation and treatment. Factors such as tumor size, grade, stage, and patient age were found to be correlated with worse prognosis, while the best overall survival was seen in patients who underwent combined surgery, chemotherapy, and radiotherapy. Black patients had significantly worse outcomes compared to White patients, with higher rates of aggressive tumor features at presentation. The most common genetic mutations observed were TP53, PIK3CA, and LRP1B.
Article
Pathology
Bryce Parkinson, Wei Chen, Tiansheng Shen, Anil Parwani, Zaibo Li
Summary: TRPS1 is a highly sensitive and specific marker for breast carcinomas, and its expression is associated with tumor subtypes and HER2 protein.
AMERICAN JOURNAL OF SURGICAL PATHOLOGY
(2022)
Article
Oncology
Clinton Yam, Nour Abuhadra, Ryan Sun, Beatriz E. Adrada, Qing-Qing Ding, Jason B. White, Elizabeth E. Ravenberg, Alyson R. Clayborn, Vicente Valero, Debu Tripathy, Senthilkumar Damodaran, Banu K. Arun, Jennifer K. Litton, Naoto T. Ueno, Rashmi K. Murthy, Bora Lim, Luis Baez, Xiaoxian Li, Aman U. Buzdar, Gabriel N. Hortobagyi, Alistair M. Thompson, Elizabeth A. Mittendori, Gaiane M. Rauch, Rosalind P. Candelaria, Lei Huo, Stacy L. Moulder, Jeffrey T. Chang
Summary: This study analyzed the clinical outcomes, survival status, and genomic profiles of patients with metaplastic breast cancer (MpBC) who received neoadjuvant therapy. The results showed that MpBC patients had a lower response rate to the therapy, shorter survival time, and distinct genetic characteristics compared to non-metaplastic triple-negative breast cancer (TNBC) patients. Furthermore, some non-MpTNBC patients exhibited similar gene expression profiles and treatment responses to MpBC.
CLINICAL CANCER RESEARCH
(2022)
Article
Oncology
Kirithiga Ramalingam, Elle Clelland, Harriet Rothschild, Firdows Mujir, Helena Record, Mandeep Kaur, Rita A. Mukhtar
Summary: This study evaluated the rates of successful breast conservation surgery (BCS) after neoadjuvant chemotherapy (NAC) in premenopausal and postmenopausal patients with invasive lobular carcinoma (ILC). The results showed that NAC was not associated with successful BCS, and menopausal status may not be a good predictor of chemotherapy response.
ANNALS OF SURGICAL ONCOLOGY
(2023)
Article
Oncology
Priyanka Narayan, Caroline E. Kostrzewa, Zhigang Zhang, Diana A. Roth O'Brien, Boris A. Mueller, John J. Cuaron, Amy J. Xu, Michael B. Bernstein, Beryl McCormick, Simon N. Powell, Atif J. Khan, Hannah Y. Wen, Lior Z. Braunstein
Summary: This study aimed to investigate the recurrence and survival outcomes of a rare subtype of breast cancer, metaplastic breast carcinoma (MBC). It was found that appropriately treated MBC patients had similar recurrence and survival rates compared to non-MBC patients, and chemotherapy and radiotherapy may help reduce the differences.
BREAST CANCER RESEARCH AND TREATMENT
(2023)
Article
Cardiac & Cardiovascular Systems
Tiuri E. Kroese, Willemieke P. M. Dijksterhuis, Peter S. N. van Rossum, Rob H. A. Verhoeven, Stella Mook, Nadia Haj Mohammad, Maarten C. C. M. Hulshof, Mark I. van Berge Henegouwen, Martijn G. H. van Oijen, Jelle P. Ruurda, Hanneke W. M. van Laarhoven, Richard van Hillegersberg
Summary: This study evaluated the management, overall survival, and prognostic factors of esophageal cancer patients with interval distant metastases. The findings suggest that the survival outcomes of these patients are influenced by treatment strategies and prognostic factors, and are comparable to those of synchronous metastatic patients.
ANNALS OF THORACIC SURGERY
(2022)
Review
Oncology
Baolin Chen, Yan Jiang, Chengmin Luo, Yuxiang Bao, Na Tan, Taolang Li, Xiaoming Cheng, Junyuan Lv
Summary: This case report describes a patient with metaplastic squamous cell carcinoma of the breast who achieved a good response to neoadjuvant chemotherapy with paclitaxel and carboplatin, followed by modified radical mastectomy. The TP regimen, commonly used for triple negative breast cancer, demonstrated effectiveness in the treatment of this rare and aggressive type of cancer.
TRANSLATIONAL CANCER RESEARCH
(2022)
Article
Oncology
Ana Alicia Tejera Hernandez, Victor Manuel Vega Benitez, Marta Pavcovich Ruiz, Juan Ramon Hernandez Hernandez
Summary: This study analyzed the clinical and histological characteristics of patients with metaplastic carcinoma of the breast with squamous differentiation. The results showed that this type of carcinoma has high local aggressiveness and rapid progression, requiring complex multidisciplinary treatment.
WORLD JOURNAL OF SURGICAL ONCOLOGY
(2022)
Article
Oncology
Audree B. Tadros, Varadan Sevilimedu, Dilip D. Giri, Emily C. Zabor, Monica Morrow, George Plitas
Summary: Metaplastic breast carcinoma (MBC) is a rare and aggressive subtype of breast cancer with poorer survival compared to other triple-negative breast cancers. Among MBC patients, those with heterologous mesenchymal subtype had the best survival, while those with squamous subtype had the worst survival. This calls for further research to identify tailored therapies for MBC's unique biology.
ANNALS OF SURGICAL ONCOLOGY
(2021)
Review
Biochemistry & Molecular Biology
Silvia Gonzalez-Martinez, Belen Perez-Mies, David Pizarro, Tamara Caniego-Casas, Javier Cortes, Jose Palacios
Summary: Metaplastic breast carcinoma (MBC) is a rare triple negative invasive cancer with poor prognosis. The resistance mechanisms of MBC may involve epithelial-mesenchymal transition (EMT) and immune response, distinguishing it from other types of breast cancer.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2021)
Article
Oncology
Huang-Chun Lien, Chia-Lang Hsu, Yen-Shen Lu, Tom Wei-Wu Chen, I. -Chun Chen, Yu-Chia Li, Chiun-Sheng Huang, Ann-Lii Cheng, Ching-Hung Lin
Summary: This study investigated the transcriptomic alterations in different components of metaplastic breast carcinoma (MpBC) and found that these alterations are associated with histological subtype and metastasis. These findings contribute to our understanding of the pathogenesis of morphologically distinct metaplasia in MpBC.
BREAST CANCER RESEARCH
(2023)
Article
Oncology
Yihong Wang, Kamaljeet Singh, Don Dizon, Teresa Graves, Ali Amin, Evgeny Yakirevich
Summary: The study investigated the response of HER2-positive breast cancer patients to neoadjuvant chemotherapy, finding that HER2 protein expression is associated with predicting NAC response and long-term prognosis.
BREAST CANCER RESEARCH AND TREATMENT
(2021)
Article
Oncology
Giovanni Corso, Samuele Frassoni, Antonia Girardi, Elisa De Camilli, Emilia Montagna, Mattia Intra, Luca Bottiglieri, Alessandra Margherita De Scalzi, Denise Mattar Fanianos, Francesca Magnoni, Alessandra Invento, Antonio Toesca, Fabio Conforti, Vincenzo Bagnardi, Giuseppe Viale, Marco Angelo Colleoni, Paolo Veronesi
Summary: The study found that metaplastic and ductal breast cancers with triple-negative phenotype are similar in terms of overall and disease-free survival. Metaplastic cancers show poor response to neoadjuvant treatment, and in the absence of novel targeted therapies, surgical treatment remains the preferred choice.
JOURNAL OF SURGICAL ONCOLOGY
(2021)
Article
Oncology
Kuo-Hsing Chen, Chia-Lang Hsu, Yu-Li Su, Chang-Tsu Yuan, Liang-In Lin, Jia-Huei Tsai, Yi-Hsin Liang, Ann-Lii Cheng, Kun-Huei Yeh
Summary: This study found that the immune contexture in the tumor microenvironment is closely associated with prognosis in patients with metastatic BRAF V600E mutant colorectal cancer. High expression of immune genes and complement activation are correlated with poor prognosis, and the complement score is strongly correlated with tumor-associated macrophage M2 signatures.
BRITISH JOURNAL OF CANCER
(2023)
Article
Gastroenterology & Hepatology
Masatoshi Kudo, Richard S. Finn, Shukui Qin, Kwang-Hyub Han, Kenji Ikeda, Ann-Lii Cheng, Arndt Vogel, Francesco Tovoli, Kazuomi Ueshima, Hiroshi Aikata, Carlos Lopez Lopez, Marc Pracht, Zhiqiang Meng, Bruno Daniele, Joong-Won Park, Daniel Palmer, Toshiyuki Tamai, Kenichi Saito, Corina E. Dutcus, Riccardo Lencioni
Summary: The study aimed to validate objective response as an independent predictor of overall survival (OS) in individuals with unresectable hepatocellular carcinoma (HCC) receiving systemic anti-angiogenic therapy. The results showed that objective response assessed by investigator-assessed mRECIST could predict the survival of patients. Further studies are needed to confirm this finding.
JOURNAL OF HEPATOLOGY
(2023)
Article
Oncology
Ching-Hung Lin, Muhammad Zahid, Wen-Hung Kuo, Ming-Yang Wang, Fu-Chang Hu, I-Chun Chen, Cheryl L. Beseler, Bodhisattwa Mondal, Yen -Shen Lu, Eleanor G. Rogan, Ann-Lii Cheng
Summary: The incidence of breast cancer among premenopausal women in East Asia has been increasing rapidly. This study found that the ratio of estrogen-DNA adducts in plasma was significantly higher in the case group compared to the control group, and it was a significant predictor of breast cancer risk in premenopausal women.
CANCER PREVENTION RESEARCH
(2023)
Article
Multidisciplinary Sciences
Pei-Wen Huang, Hsu Ouyang, Bang-Yi Hsu, Yu-Ruei Chang, Yu-Chieh Lin, Yung-An Chen, Yu-Han Hsieh, Chien-Chung Fu, Chien-Feng Li, Ching-Hung Lin, Yen-Yin Lin, Margaret Dah-Tsyr Chang, Tun-Wen Pai
Article
Oncology
Yu-Chieh Tsai, Tzu-Yin Wang, Chia-Lang Hsu, Wei-Chou Lin, Jyun-Yu Chen, Jia-Hua Li, Yeong-Shiau Pu, Ann-Lii Cheng, Jason Chia-Hsien Cheng, Sheng-Fang Su
Summary: This study found that inhibiting HDAC6 can enhance the radiosensitivity of bladder cancer and reduce the expression of genes related to cell migration, angiogenesis, and metastasis induced by radiotherapy, thereby improving therapeutic efficacy.
BRITISH JOURNAL OF CANCER
(2023)
Article
Oncology
Masatoshi Kudo, Richard S. Finn, Ann-Lii Cheng, Andrew X. Zhu, Michel Ducreux, Peter R. Galle, Naoya Sakamoto, Naoya Kato, Michitaka Nakano, Jing Jia, Arndt Vogel
Summary: This exploratory analysis examined the prognostic impact of baseline albumin-bilirubin (ALBI) score in patients with unresectable hepatocellular carcinoma (HCC) treated with atezolizumab + bevacizumab or sorafenib. The study found that atezolizumab + bevacizumab improved overall survival and progression-free survival compared to sorafenib in patients with ALBI score of 1, but not in patients with ALBI score of 2. ALBI grade appeared to be prognostic for outcomes in both treatment groups.
Article
Oncology
Philippe Merle, Masatoshi Kudo, Julien Edeline, Mohamed Bouattour, Ann-Lii Cheng, Stephen Lam Chan, Thomas Yau, Marcelo Garrido, Jennifer Knox, Bruno Daniele, Valeriy Breder, Ho Yeong Lim, Sadahisa Ogasawara, Stephane Cattan, Yee Chao, Abby B. Siegel, Ivan Martinez-Forero, Ziwen Wei, Chih-Chin Liu, Richard S. Finn
Summary: With extended follow-up, pembrolizumab demonstrated continued improvement in overall survival (OS) and progression-free survival (PFS) compared to placebo in advanced hepatocellular carcinoma (HCC) patients previously treated with sorafenib. The adverse event profile of pembrolizumab remained consistent with placebo.
Review
Public, Environmental & Occupational Health
Joanne Wing Yan Chiu, Soo Chin Lee, James Chung-man Ho, Yeon Hee Park, Ta-Chung Chao, Sung-Bae Kim, Elgene Lim, Ching-Hung Lin, Sherene Loi, Su Ying Low, Lynette Li San Teo, Winnie Yeo, Rebecca Dent
Summary: Trastuzumab deruxtecan (T-DXd), an antibody-drug conjugate targeting HER2, has shown improved outcomes for patients with HER2-positive and HER2-low metastatic breast cancer. Monitoring and managing T-DXd-related adverse events (AEs) is a growing need, and experts from the Asia-Pacific region provided recommendations based on clinical trial evidence and regional healthcare considerations. Proactive monitoring and management are crucial for maximizing the benefits of T-DXd.
Review
Oncology
Shang-Hsuan Peng, Ching-Hung Lin, I-Chun Chen, Ying-Chun Shen, Dwan-Ying Chang, Tom Wei-Wu Chen, Shu-Min Huang, Fu-Chang Hu, Yen-Shen Lu
Summary: This systematic review found that Asian patients with advanced cancers may derive superior overall survival benefits from pembrolizumab compared to non-Asian patients. However, no significant difference was found in progression-free survival. The study also identified the open-label design as a key covariate that favored non-Asian participants. These findings provide important insights into clinical research design.
Article
Oncology
Ming-Shen Dai, Ta-Chung Chao, Chang-Fang Chiu, Yen-Shen Lu, Her-Shyong Shiah, Christopher G. C. A. Jackson, Noelyn Hung, Jianguo Zhi, David L. L. Cutler, Rudolf Kwan, Douglas Kramer, Wing-Kai Chan, Albert Qin, Kuan-Chiao Tseng, Cheung Tak Hung, Tsu-Yi Chao
Summary: This study investigated the pharmacokinetics, overall response rate, and safety of weekly oral paclitaxel with encequidar in patients with advanced breast cancer. The results showed that the combination therapy produced consistent therapeutic plasma paclitaxel exposure and had a high clinical benefit rate, with a low rate of neurotoxicity.
THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY
(2023)
Article
Radiology, Nuclear Medicine & Medical Imaging
Bang-Bin Chen, Po-Chin Liang, Tiffany Ting-Fang Shih, Tsung-Hao Liu, Ying-Chun Shen, Li-Chun Lu, Zhong-Zhe Lin, Chiun Hsu, Chih-Hung Hsu, Ann-Lii Cheng, Yu-Yun Shao
Summary: Sarcopenia and myosteatosis are independent prognostic factors in patients who received immunotherapy for advanced HCC.
EUROPEAN RADIOLOGY
(2023)
